Overview

This trial is active, not recruiting.

Conditions diarrhea, gastroenteritis
Treatment rv5 (pentavalent rotavirus vaccine)
Phase phase 4
Sponsor Dennis Clements
Collaborator Merck Sharp & Dohme Corp.
Start date February 2014
End date December 2015
Trial size 60 participants
Trial identifier NCT01960725, MISP-50891, Pro00049081

Summary

This is a pilot study to assess the safety and immunogenicity of pentavalent rotavirus vaccine (RV5) when administered according to an alternate dosing schedule (2-5 weeks, 2 months and 4 months). In this interventional, open-label study, infants 2 through 5 weeks of age (14 to 41 days) will be enrolled and vaccinated with RV5 according to a 2-5 week, 2 and 4 month schedule and infants 2 months of age (56 to 83 days) will be vaccinated according to the standard recommended schedule (2, 4, and 6 months of age). Sera will be obtained from subjects one month following the final dose of vaccine and will be assayed for anti-rotavirus IgA and rotavirus neutralizing antibody responses against the G1, G2, G3, G4 and P[8] serotypes. Post dose 3 G1 serum-neutralizing antibody (SNA) geometric mean titers (GMTs) will be compared between children receiving pentavalent rotavirus vaccine (RV5) according to the alternate dosing schedule versus the standard recommended schedule. Likewise, post dose 3 G2, G3, G4 and P[8] SNA and serum rotavirus IgA GMTs will be compared between children receiving RV5 according to the alternate dosing schedule and the standard recommended schedule. The safety and tolerability of RV5 in children receiving vaccine according to the alternate dosing schedule will be described.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification bio-equivalence study
Intervention model parallel assignment
Masking open label
Primary purpose prevention
Arm
(Active Comparator)
Group will receive RV5 vaccine at 2, 4, and 6 months of age
rv5 (pentavalent rotavirus vaccine) RotaTeq
(Experimental)
Group will receive RV5 vaccine at 2-5 weeks, 2 and 4 months of age
rv5 (pentavalent rotavirus vaccine) RotaTeq

Primary Outcomes

Measure
G1 serum-neutralizing antibody
time frame: 1 month following vaccine series completion

Secondary Outcomes

Measure
G2 serum-neutralizing antibody
time frame: 1 month following vaccine series completion
G3 serum-neutralizing antibody
time frame: 1 month following vaccine series completion
G4 serum-neutralizing antibody
time frame: 1 month following vaccine series completion
P[8] serum-neutralizing antibody
time frame: 1 month following vaccine series completion

Eligibility Criteria

Male or female participants up to 83 days old.

Inclusion Criteria: 1. Male or female infants who are 14 through 41 or 56 through 83 days of age at Visit 1 (Day of initial vaccination) 2. Parent / legal guardian has read and signed the informed consent document 3. Child and parent / legal guardian is available for the entire study period and can be reached by telephone 4. Healthy infant as determined by medical history and by a baseline physical examination 5. Infant weight at time of enrollment must exceed birth weight Exclusion Criteria: 1. History of hypersensitivity to the vaccine or any component of the vaccine 2. History of Severe Combined Immunodeficiency Disease (SCID) 3. History of immunocompromise ( infant is known to be HIV positive, to have hypogammaglobulinemia or to have an underlying malignancy) 4. History of intussusception 5. Any clinically significant history of gastrointestinal disease including active acute gastrointestinal illness, chronic diarrhea, failure to thrive, congenital abdominal disorders, abdominal surgery or liver disease 6. Prior receipt of a rotavirus vaccine 7. Less than 37 weeks gestation 8. The subject has participated in a study with an experimental agent within one month of enrollment in the study or anticipated receipt of an experimental agent during participation in the study 9. Receipt of blood products within 4 weeks of study vaccination 10. Receipt of a live virus vaccine within 4 weeks of study vaccination or an inactivated vaccine within 2 weeks. Concomitant administration of routinely recommended vaccines is allowed. A dose of hepatitis B vaccine administered in the birthing hospital is permitted. Planned routine use of inactivated influenza vaccine for children over 6 months of age is permitted. 11. Acute illness within 48 hours of vaccination (axillary temperature of 100.4°F or higher, 3 or more grossly watery stools, vomiting). (Infants with stable unchanged gastroesophageal reflux may be enrolled). 12. Insufficient weight gain requiring future weight checks in addition to routine scheduled well child visits 13. The subject has any condition that the investigator believes would put the subject at an increased risk of injury or would render the subject unable to complete the trial or fulfill the requirements of the study protocol. 14. Household contact who is immunodeficient (any malignancies or otherwise immunocompromised, primary immunodeficiency, receiving immunosuppressive therapy)

Additional Information

Official title An Open-label, Pilot Study to Compare the Safety and Immunogenicity of an Alternate Dosing Schedule (2-5 Weeks, 2 Months, and 4 Months) for Pentavalent Rotavirus Vaccine (RotaTeq) to the Standard Recommended Schedule (2, 4, and 6 Months)
Principal investigator Dennis A Clements, MD, PhD
Trial information was received from ClinicalTrials.gov and was last updated in January 2016.
Information provided to ClinicalTrials.gov by Duke University.